Meeting
2021 ASCO Annual Meeting
Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
Authors
Eisaku Miyauchi
Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan
Eisaku Miyauchi , Satoshi Morita , Atsushi Nakamura , Yukio Hosomi , Kana Watanabe , Satoshi Ikeda , Masahiro Seike , Yuka Fujita , Koichi Minato , Ryo Ko , Toshiyuki Harada , Koichi Hagiwara , Kunihiko Kobayashi , Toshihiro Nukiwa , Akira Inoue
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000006340
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9081)
DOI
10.1200/JCO.2021.39.15_suppl.9081
Abstract #
9081
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations.
First Author: Satoshi Oizumi
Poster
2014 ASCO Annual Meeting
Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902.
First Author: Satoshi Oizumi
Poster
2024 ASCO Annual Meeting
Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).
First Author: Yuki Sato
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).
First Author: Wenfeng Fang